Fighting doxorubicin-induced cardiotoxicity with adiponectin

Cardiovascular Research

Volumn 89, Issue 2, 2011, Pages 262-264

  McTiernan, Charles F ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ADIPONECTIN; ADIPONECTIN RECEPTOR; ADIPONECTIN RECEPTOR 1; ADIPONECTIN RECEPTOR 2; CYTOCHROME C; DOXORUBICIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

APOPTOSIS; CARDIOTOXICITY; DRUG MECHANISM; DRUG METABOLISM; HEART FAILURE; HUMAN; LIPID PEROXIDATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION;

ADIPONECTIN; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CARDIOMYOPATHIES; DOXORUBICIN; FIBROSIS; HUMANS; MICE; MYOCARDIUM; MYOCYTES, CARDIAC; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 78751477709     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvq393     Document Type: Review

References (16)

1. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998;339: 900-905.
2. Zhao Y, McLaughlin D, Robinson E, Harvey AP, Hookham MB, Shah AM et al. Nox2 NADPH oxidase promotes pathologic cardiac remodeling associated with doxorubicin chemotherapy. Cancer Res 2010;70:9287-9297.
3. Mukhopadhyay P, Rajesh M, Bátkai S, Kashiwaya Y, Haskó G, Liaudet L et al. Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro. Am J Physiol Heart Circ Physiol 2009;296:1466-1483.
4. Childs AC, Phaneuf SL, Dirks AJ, Phillips T, Leeuwenburgh C. Doxorubicin treatment in vivo causes cytochrome c release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2:Bax ratio. Cancer Res 2002;62:4592-4598.
5. Zhu W, Soonpaa MH, Chen H, Shen W, Payne RM, Liechty EA et al. Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway. Circulation 2009;119:99-106.
6. Konishi M, Haraguchi G, Ohigashi H, Ishihara T, Saito K, Nakano Y et al. Adiponectin protects against doxorubicin-induced cardiomyopathy by anti-apoptotic effects through AMPK up-regulation. Cardiovasc Res 2011;89:309-319.
7. Yamauchi T, Kamon J,Waki H, Terauchi Y, Kubota N, Hara K et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2001;7:941-946.
8. Hardie DG, Hawley SA. AMP-activated protein kinase: the energy charge hypothesis revisited. BioEssays 2001;23:1112-1119.
9. Mitra MS, Donthamsetty S, White B, Mehendale HM. High fat diet-fed obese rats are highly sensitive to doxorubicin-induced cardiotoxicity. Toxicol Appl Pharmacol 2008; 231:413-422.
10. Mitra MS, Donthamsetty S, White B, Latendresse JR, Mehendale HM. Mechanism of protection of moderately diet restricted rats against doxorubicin-induced acute cardiotoxicity. Toxicol Appl Pharmacol 2007;225:90-101.
11. Wijesekara N, Krishnamurthy M, Bhattacharjee A, Suhail A, Sweeney G, Wheeler MB. Adiponectin-induced ERK and Akt phosphorylation protects against pancreatic beta cell apoptosis and increases insulin gene expression and secretion. J Biol Chem 2010;285:33623-33631.
12. Thundyil J, Tang S, Okun E, Shah K, Karamyan VT, Li Y et al. Evidence that adiponectin receptor 1 activation exacerbates ischemic neuronal death. Exp Trans Stroke Med 2010;2:15-23.
13. Bräkenhielm E, Veitonmäki N, Cao R, Kihara S, Matsuzawa Y, Zhivotovsky B et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspasemediated endothelial cell apoptosis. Proc Natl Acad Sci USA 2004;101:2476-2481.
14. Kobayashi H, Ouchi N, Kihara S, Walsh K, Kumada K, Abe Y et al. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res 2004;94:e27-e31. doi:10.1161/01.RES.0000119921.86460.37.
15. Ouchi N, Shibata R,Walsh K. Cardioprotection by adiponectin. Trends Cardiovasc Med 2006;16:141-146. doi:10.1016/j.tcm.2006.03.001. (Pubitemid 43867326)
16. Zhou G, Sebhat IK, Zhang BB. AMPK activators-potential therapeutics for metabolic and other diseases. Acta Physiol 2009;196:175-190. doi:10.1111/j.1748-1716.2009. 01967.x.